PEcoma市场：现况分析与预测（2023-2030）

2022年PEcoma城市成长率4,550万米元，节省2023年至2030年年复合成长率5%。

依类型分类、市场分类、诊断及治疗。 2022年，市场将以治疗类型为主导。 在治疗选择上，手术是主要的治疗选择，特殊治疗是局部疾病。 手术彻底切除是目标，因此有可能显着改善患者的病情。 然而，根据夜间的时间段，手术的效果会受到限制。 因此，对于未经有效治疗就无法切除或转移的PEcoma的治疗材料的需求持续增加。

最终使用部门、市场部门医院、医疗中心等 其中，2022年主要市价依医院类型划分。 主要原因是手术治疗先进，医院拥有先进的医疗设备和专业知识。

业务市场介绍，将市场划分：北碚（Mikuni、加拿大大学、北碚等地区）、Pershu（Tokkoku、英国、Hokoku、Eidali、Xibanga、Pershu等地区）、亚太地区（中国、日本）、印度、韩国、澳门等）等世界各地。 到2022年，PEcoma市场的价格将会上涨。 推动北美市场成长的主要因素是各国基础医疗设施的扩张以及医疗卫生支出的增加。

我录

第一章市场介绍

• 市场定义
• 主要目标
• 有兴趣的人
• 有限

第 2 章研究方法/建立

• 调查过程
• 调查方法
• 访客简报

第三章市场对接

第四章执行总结

第五章新型冠状病毒感染 (COVID-19) 对全球 PEcoma 市场的影响

第 6 章 2020-2030 年全球 PEcoma 市场进入

第七章分类市场洞察

• 考试
• 作弊
  • 化疗
  • 火车治疗
  • 放射治疗
  • 其他

第 8 章最终用户市场洞察

• 医院
• 临床检验中心
• 其他

第 9 章区域市场洞察

• Kitabi PEcoma 市场
  • 三国
  • 加那大学
  • 北见其他地区
• 九州PEcoma市场
  • 德国
  • 英语
  • 北国
  • 巨大的好处
  • 西番贺
  • 其他九州地区
• 艾泰区PEcoma市场
  • 中国
  • 日本
  • 印度
  • 亚洲其他国家/地区
• 其他地区 PEcoma 市场

第 10 章 PEcoma 市场动态

• 市场驱动因素
• 市场挑战
• 影响分析

第 11 章 PEcoma 市场机会

第十二章 PEcoma 市场趋势

第十三章供给与需求方法分析

• 需求分析
• 供给面分析

第14章分析

第 15 章赛道视图

• 竞争状况
  • Hatoku 五力分析

第十六章公司摘要

• Sarcoma Oncology Research Center LLC
• Aadi Bioscience Inc
• Novartis Pharmaceuticals
• CENTOGENE GmbH Rostock
• Antia Therapeutics AG
• InCor Heart Institute
• Children's Hospital Medical Center
• Johnson & Johnson
• Pfizer
• Mylan N.V.

第十七章免责声明

Perivascular epithelioid cell tumors, also known as PEComa, represent a rare type of mesenchymal neoplasm that originates from perivascular epithelioid cells. These tumors can occur in various organs throughout the body, such as the uterus, kidney, liver, and gastrointestinal tract. PEComa is considered a challenging disease due to its rarity and the limited understanding surrounding its pathogenesis. Further, continuous rise in the incidences of Pecoma is also driving the market. For instance, as per the National Organization for Rare Disorders, Malignant PEComas are estimated to be diagnosed in 0.12 to 0.24 per one million people.

The PEcoma market was valued at USD 45.5 million in 2022 and is expected to grow at a CAGR of around 5% from 2023-2030.

Based on the type, the market is segmented into diagnosis and Treatment. The treatment category dominated the market in 2022. Regarding therapeutic options, surgery is the primary treatment modality for PEComa, particularly for localized disease. Complete surgical resection is the aim, as it significantly improves patients' outcomes. However, the effectiveness of surgery in advanced or metastatic cases is limited. Thus, there is a growing demand for targeted therapies that can effectively treat unresectable or metastatic PEComa.

On the basis of end-users, the market is categorized into Hospitals, diagnostic centers, and Others. Among these, the hospital's category held a significant market share in 2022. This is mainly due to the high volume of PEcome surgeries and treatments performed in hospitals, as well as the availability of advanced medical equipment and expertise in this setting.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America held dominating share of PEcoma market in 2022. The presence of well-established healthcare infrastructure, along with the increasing healthcare expenditure in the countries is the major attributing factor for the market growth in North America.

Some of the major players operating in the market include: Sarcoma Oncology Research Center LLC, Aadi Bioscience Inc, Novartis Pharmaceuticals, CENTOGENE GmbH Rostock, Antia Therapeutics AG, InCor Heart Institute, Children's Hospital Medical Center, Johnson & Johnson, Pfizer, and Mylan N.V.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the PEcoma Market
• 2.2. Research Methodology of the PEcoma Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL PECOMA MARKET COVID-19 IMPACT

6 GLOBAL PECOMA MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Diagnosis
• 7.2. Treatment
  • 7.2.1. Chemotherapy
  • 7.2.2. Targeted Therapy
  • 7.2.3. Radiotherapy
  • 7.2.4. Others

8 MARKET INSIGHTS BY END USER

• 8.1. Hospitals
• 8.2. Diagnostic Centers
• 8.3. Others

9 MARKET INSIGHTS BY REGION

• 9.1. North America PEcoma Market
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe PEcoma Market
  • 9.2.1. Germany
  • 9.2.2. UK
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific PEcoma Market
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of APAC
• 9.4. Rest of the World PEcoma Market

10 PECOMA MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 PECOMA MARKET OPPORTUNITIES

12 PECOMA MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Sarcoma Oncology Research Center LLC
• 16.2. Aadi Bioscience Inc
• 16.3. Novartis Pharmaceuticals
• 16.4. CENTOGENE GmbH Rostock
• 16.5. Antia Therapeutics AG
• 16.6. InCor Heart Institute
• 16.7. Children's Hospital Medical Center
• 16.8. Johnson & Johnson
• 16.9. Pfizer
• 16.10. Mylan N.V.

17 DISCLAIMER